{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:57:12Z","timestamp":1790650632719,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1009428","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000}}],"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enanta Pharmaceuticals, Inc."}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>\n                    EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). It is highly active against all RSV-A and B laboratory strains and clinical isolates tested\n                    <jats:italic>in vitro<\/jats:italic>\n                    in various cell lines and assays, with half-maximal effective concentrations (EC\n                    <jats:sub>50<\/jats:sub>\n                    s) of 21, 23 and 64 nM against Long (A), M37 (A) and VR-955 (B) strains, respectively, in the primary human bronchial epithelial cells (HBECs). EDP-938 inhibits RSV at a post-entry replication step of the viral life cycle as confirmed by time-of-addition study, and the activity appears to be mediated by viral nucleoprotein (N).\n                    <jats:italic>In vitro<\/jats:italic>\n                    resistance studies suggest that EDP-938 presents a higher barrier to resistance compared to viral fusion or non-nucleoside L polymerase inhibitors with no cross-resistance observed. Combinations of EDP-938 with other classes of RSV inhibitors lead to synergistic antiviral activity\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Finally, EDP-938 has also been shown to be efficacious\n                    <jats:italic>in vivo<\/jats:italic>\n                    in a non-human primate model of RSV infection.\n                  <\/jats:p>","DOI":"10.1371\/journal.ppat.1009428","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T13:40:35Z","timestamp":1615815635000},"page":"e1009428","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-7545","authenticated-orcid":true,"given":"Michael H. J.","family":"Rhodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7301-8058","authenticated-orcid":true,"given":"Nicole V.","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3507-7652","authenticated-orcid":true,"given":"Jonathan","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Noton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0783-7498","authenticated-orcid":true,"given":"Rachel","family":"Fearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6079-1997","authenticated-orcid":true,"given":"Thomas P.","family":"Blaisdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Panarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Shook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yat Sun","family":"Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"issue":"9875","key":"ppat.1009428.ref001","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(12)61901-1","article-title":"Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis","volume":"381","author":"H Nair","year":"2013","journal-title":"Lancet"},{"issue":"17","key":"ppat.1009428.ref002","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"AR Falsey","year":"2005","journal-title":"N Engl J Med."},{"issue":"1","key":"ppat.1009428.ref003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12879-018-3002-3","article-title":"Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study","volume":"18","author":"O Chatzis","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"10098","key":"ppat.1009428.ref004","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"T Shi","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"ppat.1009428.ref005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","article-title":"Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997\u20132006","volume":"31","author":"LJ Stockman","year":"2012","journal-title":"Pediatr Infect Dis J."},{"issue":"10","key":"ppat.1009428.ref006","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1016\/S2214-109X(17)30344-3","article-title":"Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series","volume":"5","author":"NM Scheltema","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"2","key":"ppat.1009428.ref007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4254\/wjh.v8.i2.123","article-title":"Ribavirin: Past, present and future","volume":"8","author":"V Loustaud-Ratti","year":"2016","journal-title":"World J Hepatol"},{"issue":"7","key":"ppat.1009428.ref008","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.healun.2015.01.009","article-title":"Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency","volume":"34","author":"FS Burrows","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"ppat.1009428.ref009","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1128\/AAC.40.11.2555","article-title":"Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation","volume":"40","author":"DM Lewinsohn","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ppat.1009428.ref010","first-page":"33","article-title":"Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)","volume":"1","author":"JM Geskey","year":"2007","journal-title":"Biologics."},{"key":"ppat.1009428.ref011","first-page":"3","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"PL Collins","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"ppat.1009428.ref012","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume":"58","author":"RL Mackman","year":"2015","journal-title":"J Med Chem"},{"key":"ppat.1009428.ref013","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients","author":"RF Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ppat.1009428.ref014","article-title":"A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract","author":"FM Marty","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ppat.1009428.ref015","unstructured":"Hanfelt-Goade D. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial of Presatovir (GS-5806), a Novel Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Hospitalized Adults. NEW INSIGHTS IN ACUTE PULMONARY INFECTIONS.A4457-A"},{"key":"ppat.1009428.ref016","article-title":"Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus","author":"K Stray","year":"2020","journal-title":"J Infect Dis."},{"key":"ppat.1009428.ref017","article-title":"Assessment of drug resistance during phase 2b clinical trials of presatovir in adults naturally infected with respiratory syncytial virus","author":"DP Porter","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ppat.1009428.ref018","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/jiy227","article-title":"Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study","volume":"218","author":"M Stevens","year":"2018","journal-title":"J Infect Dis"},{"issue":"13","key":"ppat.1009428.ref019","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor","volume":"62","author":"X Zheng","year":"2019","journal-title":"J Med Chem"},{"issue":"2","key":"ppat.1009428.ref020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01884-19","article-title":"A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein","volume":"64","author":"J DeVincenzo","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ppat.1009428.ref021","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4\u2019-chloromethyl-2\u2019-deoxy-3\u2019,5\u2019-di-O-isobutyryl-2\u2019-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"G Wang","year":"2015","journal-title":"J Med Chem"},{"issue":"24","key":"ppat.1009428.ref022","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1016\/j.bmcl.2013.10.018","article-title":"Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor","volume":"23","author":"H Xiong","year":"2013","journal-title":"Bioorg Med Chem Lett."},{"key":"ppat.1009428.ref023","unstructured":"Coates M, Brookes D, Allen H, Fordyce E, Colley T, Hunt F, et al. Preclinical characterization of PC786, a potent antiviral inhibitor of respiratory syncytial virus replication. XVIII International Symposium on Respiratory Viral Infections; March 31 \u2013April 2, 2016; Lisbon, Portugal2016."},{"key":"ppat.1009428.ref024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics\u2014A meeting report from the 6th isirv Antiviral Group conference","volume":"167","author":"JH Beigel","year":"2019","journal-title":"Antiviral Res"},{"issue":"21","key":"ppat.1009428.ref025","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral als-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"JP DeVincenzo","year":"2015","journal-title":"N Engl J Med."},{"key":"ppat.1009428.ref026","unstructured":"SEC filing 2019. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/200406\/000020040619000016\/a20190321alios8-k.htm."},{"issue":"4","key":"ppat.1009428.ref027","first-page":"645","article-title":"American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn","volume":"99","author":"Respiratory syncytial virus immune globulin intravenous: indications for use","year":"1997","journal-title":"Pediatrics"},{"issue":"7","key":"ppat.1009428.ref028","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm051185t","article-title":"1,4-Benzodiazepines as inhibitors of respiratory syncytial virus","volume":"49","author":"MC Carter","year":"2006","journal-title":"J Med Chem."},{"issue":"9","key":"ppat.1009428.ref029","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/AAC.00211-07","article-title":"RSV604, a novel inhibitor of respiratory syncytial virus replication","volume":"51","author":"J Chapman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ppat.1009428.ref030","volume-title":"Antiviral Drugs: From Basic Discovery Through Clinical Trials","author":"J Chapman","year":"2011","edition":"1"},{"key":"ppat.1009428.ref031","unstructured":"Shook BC, Kim IJ, Blaisdell TP, Yu J, Panarese J, Or YS. Benzodiazepine derivatives as RSV inhibitors. WO2017015449. 2017."},{"issue":"2","key":"ppat.1009428.ref032","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1128\/AAC.04119-14","article-title":"Mechanism of action for respiratory syncytial virus inhibitor RSV604","volume":"59","author":"S Challa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ppat.1009428.ref033","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1128\/AAC.02540-14","article-title":"Characterization of a respiratory syncytial virus L protein inhibitor","volume":"58","author":"CL Tiong-Yip","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ppat.1009428.ref034","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41467-017-00655-9","article-title":"Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus","volume":"8","author":"V Rincheval","year":"2017","journal-title":"Nat Commun."},{"issue":"10","key":"ppat.1009428.ref035","doi-asserted-by":"crossref","first-page":"e1008987","DOI":"10.1371\/journal.ppat.1008987","article-title":"Polymerase-tagged respiratory syncytial virus reveals a dynamic rearrangement of the ribonucleocapsid complex during infection","volume":"16","author":"EL Blanchard","year":"2020","journal-title":"PLoS Pathog."},{"issue":"1","key":"ppat.1009428.ref036","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/viro.1993.1366","article-title":"Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein","volume":"195","author":"J Garcia","year":"1993","journal-title":"Virology"},{"issue":"5","key":"ppat.1009428.ref037","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01202-20","article-title":"Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies In Vivo and In Vitro","volume":"11","author":"M Galloux","year":"2020","journal-title":"mBio"},{"issue":"6","key":"ppat.1009428.ref038","doi-asserted-by":"crossref","first-page":"e1004995","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus rna polymerase by 2\u2019-fluoro-4\u2019-chloromethyl-cytidine triphosphate","volume":"11","author":"J Deval","year":"2015","journal-title":"PLoS Pathog"},{"key":"ppat.1009428.ref039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"TC Chou","year":"1984","journal-title":"Adv Enzyme Regul."},{"key":"ppat.1009428.ref040","unstructured":"CDC report 2019. Available from: https:\/\/wwwn.cdc.gov\/nndss\/conditions\/respiratory-syncytial-virus-associated-mortality\/case-definition\/2019\/."},{"issue":"12","key":"ppat.1009428.ref041","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/bph.14221","article-title":"Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium","volume":"175","author":"DW Brookes","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"21","key":"ppat.1009428.ref042","doi-asserted-by":"crossref","first-page":"11129","DOI":"10.1128\/JVI.01612-15","article-title":"A Druggable Pocket at the Nucleocapsid\/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus","volume":"89","author":"M Ouizougun-Oubari","year":"2015","journal-title":"J Virol"},{"issue":"16","key":"ppat.1009428.ref043","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1128\/JVI.00058-12","article-title":"Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein","volume":"86","author":"M Galloux","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"ppat.1009428.ref044","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vaccine.2016.11.060","article-title":"ViroSpot microneutralization assay for antigenic characterization of human influenza viruses","volume":"35","author":"CA van Baalen","year":"2017","journal-title":"Vaccine"},{"key":"ppat.1009428.ref045","first-page":"1","article-title":"Influenza virus and RSV ViroSpot\u2122 Assays for high-throughput virology testing","author":"CAv Baalen","year":"2020","journal-title":"Viroclinics biosciences"},{"issue":"1","key":"ppat.1009428.ref046","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jviromet.2004.02.020","article-title":"A simplified plaque assay for respiratory syncytial virus\u2014direct visualization of plaques without immunostaining","volume":"120","author":"JL McKimm-Breschkin","year":"2004","journal-title":"J Virol Methods"},{"key":"ppat.1009428.ref047","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4939-6964-7_8","article-title":"BAC-Based Recovery of Recombinant Respiratory Syncytial Virus (RSV)","volume":"1602","author":"CC Stobart","year":"2017","journal-title":"Methods Mol Biol."},{"issue":"5","key":"ppat.1009428.ref048","doi-asserted-by":"crossref","first-page":"e0126959","DOI":"10.1371\/journal.pone.0126959","article-title":"Antiviral activity of tmc353121, a respiratory syncytial virus (rsv) fusion inhibitor, in a non-human primate model","volume":"10","author":"G Ispas","year":"2015","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1009428","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1009428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T16:44:07Z","timestamp":1616690647000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1009428"}},"subtitle":[],"editor":[{"given":"Mark","family":"Krystal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1009428","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}